Harrow, Inc. Operating Lease, Expense
Harrow, Inc. (HROW) reported Operating Lease, Expense of $319.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-05-13
- Harrow, Inc. operating lease, expense for the quarter ending 2024-03-31 was $319.00K, a 3.24% increase year-over-year.
- Harrow, Inc. operating lease, expense for the quarter ending 2023-12-31 was $306.00K, a 0.65% decline year-over-year.
- Harrow, Inc. operating lease, expense for the quarter ending 2023-09-30 was $309.00K, a 0.00% change year-over-year.
- Harrow, Inc. operating lease, expense for the quarter ending 2023-06-30 was $308.00K, a 17.56% increase year-over-year.
- Harrow, Inc. operating lease, expense for fiscal 2023 was $1.23M, a 10.30% increase from fiscal 2022.
- Harrow, Inc. operating lease, expense for fiscal 2022 was $1.12M, a 22.48% increase from fiscal 2021.
- Harrow, Inc. operating lease, expense for fiscal 2021 was $912.00K, a 14.45% decline from fiscal 2020.
- Harrow, Inc. operating lease, expense for fiscal 2020 was $1.07M, a 19.51% increase from fiscal 2019.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $319.00K 10-Q · filed 2024-05-13 | $625.00K derived: sum of 2 quarters · filed 2024-05-13 | $934.00K derived: sum of 3 quarters · filed 2024-05-13 | $1.24M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $306.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $615.00K derived: sum of 2 quarters · filed 2024-03-19 | $923.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.23M 10-K · filed 2024-03-19 |
| 2023-09-30 | $309.00K 10-Q · filed 2023-11-13 | $617.00K derived: sum of 2 quarters · filed 2023-11-13 | $926.00K 10-Q · filed 2023-11-13 | $1.23M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-06-30 | $308.00K 10-Q · filed 2023-08-09 | $617.00K 10-Q · filed 2023-08-09 | $925.00K derived: sum of 3 quarters · filed 2024-05-13 | $1.23M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-03-31 | $309.00K 10-Q · filed 2024-05-13 | $617.00K derived: sum of 2 quarters · filed 2024-05-13 | $926.00K derived: sum of 3 quarters · filed 2024-05-13 | $1.19M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $617.00K derived: sum of 2 quarters · filed 2024-03-19 | $879.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.12M 10-K · filed 2024-03-19 |
| 2022-09-30 | $309.00K 10-Q · filed 2023-11-13 | $571.00K derived: sum of 2 quarters · filed 2023-11-13 | $809.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $262.00K 10-Q · filed 2023-08-09 | $500.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $238.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $912.00K 10-K · filed 2023-03-23 | |||
| 2021-03-31 | $261.00K 10-Q · filed 2022-05-05 | $511.00K derived: sum of 2 quarters · filed 2022-05-05 | $772.00K derived: sum of 3 quarters · filed 2022-05-05 | $1.05M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $511.00K derived: sum of 2 quarters · filed 2022-03-10 | $791.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.07M 10-K · filed 2022-03-10 |
| 2020-09-30 | $261.00K 10-Q · filed 2020-11-09 | $541.00K derived: sum of 2 quarters · filed 2020-11-09 | $816.00K 10-Q · filed 2020-11-09 | $1.02M derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-06-30 | $280.00K 10-Q · filed 2020-08-10 | $555.00K 10-Q · filed 2020-08-10 | $755.00K derived: sum of 3 quarters · filed 2021-05-11 | $987.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-03-31 | $278.00K 10-Q · filed 2021-05-11 | $475.00K derived: sum of 2 quarters · filed 2021-05-11 | $707.00K derived: sum of 3 quarters · filed 2021-05-11 | $939.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $429.00K derived: sum of 2 quarters · filed 2021-03-08 | $661.00K derived: sum of 3 quarters · filed 2021-03-08 | $892.00K 10-K · filed 2021-03-08 |
| 2019-09-30 | $232.00K 10-Q · filed 2019-11-13 | $464.00K derived: sum of 2 quarters · filed 2019-11-13 | $695.00K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $232.00K 10-Q · filed 2019-08-14 | $464.00K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $234.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |